Literature DB >> 20075045

Clinical COPD phenotypes: a novel approach using principal component and cluster analyses.

P-R Burgel1, J-L Paillasseur, D Caillaud, I Tillie-Leblond, P Chanez, R Escamilla, I Court-Fortune, T Perez, P Carré, N Roche.   

Abstract

Classification of chronic obstructive pulmonary disease (COPD) is usually based on the severity of airflow limitation, which may not reflect phenotypic heterogeneity. Here, we sought to identify COPD phenotypes using multiple clinical variables. COPD subjects recruited in a French multicentre cohort were characterised using a standardised process. Principal component analysis (PCA) was performed using eight variables selected for their relevance to COPD: age, cumulative smoking, forced expiratory volume in 1 s (FEV(1)) (% predicted), body mass index, exacerbations, dyspnoea (modified Medical Research Council scale), health status (St George's Respiratory Questionnaire) and depressive symptoms (hospital anxiety and depression scale). Patient classification was performed using cluster analysis based on PCA-transformed data. 322 COPD subjects were analysed: 77% were male; median (interquartile range) age was 65.0 (58.0-73.0) yrs; FEV(1) was 48.9 (34.1-66.3)% pred; and 21, 135, 107 and 59 subjects were classified in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 1, 2, 3 and 4, respectively. PCA showed that three independent components accounted for 61% of variance. PCA-based cluster analysis resulted in the classification of subjects into four clinical phenotypes that could not be identified using GOLD classification. Importantly, subjects with comparable airflow limitation (FEV(1)) belonged to different phenotypes and had marked differences in age, symptoms, comorbidities and predicted mortality. These analyses underscore the need for novel multidimensional COPD classification for improving patient care and quality of clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20075045     DOI: 10.1183/09031936.00175109

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  89 in total

1.  Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene.

Authors:  Jin Hwa Lee; Michael H Cho; Merry-Lynn N McDonald; Craig P Hersh; Peter J Castaldi; James D Crapo; Emily S Wan; Jennifer G Dy; Yale Chang; Elizabeth A Regan; Megan Hardin; Dawn L DeMeo; Edwin K Silverman
Journal:  Respir Med       Date:  2014-08-11       Impact factor: 3.415

2.  Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts.

Authors:  Peter J Castaldi; Marta Benet; Hans Petersen; Nicholas Rafaels; James Finigan; Matteo Paoletti; H Marike Boezen; Judith M Vonk; Russell Bowler; Massimo Pistolesi; Milo A Puhan; Josep Anto; Els Wauters; Diether Lambrechts; Wim Janssens; Francesca Bigazzi; Gianna Camiciottoli; Michael H Cho; Craig P Hersh; Kathleen Barnes; Stephen Rennard; Meher Preethi Boorgula; Jennifer Dy; Nadia N Hansel; James D Crapo; Yohannes Tesfaigzi; Alvar Agusti; Edwin K Silverman; Judith Garcia-Aymerich
Journal:  Thorax       Date:  2017-06-21       Impact factor: 9.139

3.  Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema.

Authors:  Peter J Castaldi; Jennifer Dy; James Ross; Yale Chang; George R Washko; Douglas Curran-Everett; Andre Williams; David A Lynch; Barry J Make; James D Crapo; Russ P Bowler; Elizabeth A Regan; John E Hokanson; Greg L Kinney; Meilan K Han; Xavier Soler; Joseph W Ramsdell; R Graham Barr; Marilyn Foreman; Edwin van Beek; Richard Casaburi; Gerald J Criner; Sharon M Lutz; Steven I Rennard; Stephanie Santorico; Frank C Sciurba; Dawn L DeMeo; Craig P Hersh; Edwin K Silverman; Michael H Cho
Journal:  Thorax       Date:  2014-02-21       Impact factor: 9.139

4.  Identification of Phenotypes in People with COPD: Influence of Physical Activity, Sedentary Behaviour, Body Composition and Skeletal Muscle Strength.

Authors:  Rafaella F Xavier; Ana Carolina A C Pereira; Aline C Lopes; Vinícius Cavalheri; Regina M C Pinto; Alberto Cukier; Ercy M C Ramos; Celso R F Carvalho
Journal:  Lung       Date:  2018-11-14       Impact factor: 2.584

5.  Discretization of continuous features in clinical datasets.

Authors:  David M Maslove; Tanya Podchiyska; Henry J Lowe
Journal:  J Am Med Inform Assoc       Date:  2012-10-11       Impact factor: 4.497

6.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

7.  Subtypes of patients experiencing exacerbations of COPD and associations with outcomes.

Authors:  Inmaculada Arostegui; Cristobal Esteban; Susana García-Gutierrez; Marisa Bare; Nerea Fernández-de-Larrea; Eduardo Briones; José M Quintana
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

8.  Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index.

Authors:  Miguel J Divo; Carlos Cabrera; Ciro Casanova; Jose M Marin; Victor M Pinto-Plata; Juan P de-Torres; Javier Zulueta; Jorge Zagaceta; Pablo Sanchez-Salcedo; Juan Berto; Claudia Cote; Bartolome R Celli
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 9.  A review of the literature on symptom clusters in studies that included oncology patients receiving primary or adjuvant chemotherapy.

Authors:  Carmen Ward Sullivan; Heather Leutwyler; Laura B Dunn; Christine Miaskowski
Journal:  J Clin Nurs       Date:  2017-10-10       Impact factor: 3.036

Review 10.  Heterogeneity of chronic obstructive pulmonary disease: from phenotype to genotype.

Authors:  Xu Chen; Xiaomao Xu; Fei Xiao
Journal:  Front Med       Date:  2013-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.